Publication | Open Access

Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

Further-line TreatmentOncologyMedicineMetronomic TherapyBronchial NeoplasmReal-world EfficacyCancer TreatmentPharmacologyRadiation OncologyLung Cancer